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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
glucosamine and maintenance of normal joint cartilage pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Merck Consumer Healthcare, submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to glucosamine, 
formulated as glucosamine sulphate or hydrochloride, and maintenance of normal joint cartilage. Glucosamine is 
sufficiently characterised. The claimed effect is “contributes to the maintenance of normal joint cartilage”. The 
target population as proposed by the applicant is the general population, and in particular people exposing their 
joints to high mechanical load and people with joint cartilage deterioration due to normal ageing. The Panel 
considers that the maintenance of normal joint cartilage is a beneficial physiological effect. The applicant 
provided references to studies in patients with osteoarthritis, in healthy subjects, in animals and in vitro as being 
pertinent to the health claim. In weighing the evidence, the Panel took into account that no human studies were 
provided from which conclusions could be drawn on the effect of dietary glucosamine on the maintenance of 
cartilage in individuals without osteoarthritis, and that the evidence provided in the in vitro and animal studies in 
support of the biological plausibility for a possible contribution of dietary glucosamine to the maintenance of 
joint cartilage in humans is weak. The Panel concludes that a cause and effect relationship has not been 
established between the consumption of glucosamine and maintenance of normal joint cartilage in individuals 
without osteoarthritis. © European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Merck Consumer Healthcare, submitted pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic 
Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a 
health claim related to glucosamine and maintenance of normal joint cartilage. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food constituent that is the subject of the health claim is glucosamine, formulated as glucosamine 
sulphate or hydrochloride. The Panel considers that glucosamine is sufficiently characterised. 
The claimed effect is “contributes to the maintenance of normal joint cartilage”. The target population 
as proposed by the applicant is the general population, and in particular people exposing their joints to 
high mechanical load, for example through extensive sports activities or obesity, and people with joint 
cartilage deterioration due to normal ageing. From the information provided, the Panel notes that the 
claimed effect relates to the maintenance of joint cartilage. The Panel considers that the maintenance 
of normal joint cartilage is a beneficial physiological effect. 
In the original application, the applicant identified a total of 61 references as being pertinent to the 
health claim. These references comprised 20 references describing 12 human intervention studies, 
13 reviews on the effects of glucosamine supplementation on maintenance of joints, four animal 
studies on the effects of glucosamine on joints, 14 in vitro studies on the effects of glucosamine on 
cartilage cells/tissues, nine studies in humans and/or animals on the bioavailability of glucosamine, 
and one unpublished narrative review. 
Nineteen references were provided that report on 11 human intervention studies. These studies 
addressed the effects of glucosamine sulphate or glucosamine hydrochloride on joint-related 
outcomes in patients with clinical diagnosis of degenerative osteoarthritis (OA), mainly of the knee. 
The applicant proposed that results from these studies in patients with OA could be extrapolated to 
subjects without OA on the assumption that cartilage degeneration occurs by the same metabolic 
pathways and mechanisms during progression of OA as in pre-arthritic conditions, and that 
glucosamine may be expected to have similar effects on joint tissues with and without OA. 
The Panel notes that while a number of factors which may contribute to cartilage degeneration in the 
development (onset) and progression of OA have been identified, the term OA denotes a number of 
pathological degenerative processes of one or more joints of complex and variable aetiology for 
which no common pathological pathway has been described. The Panel also notes, in particular, that 
the pathobiology of the onset and early progression of OA is poorly defined. The evidence provided 
by consensus opinions/reports from authoritative bodies indicates that normal cells and tissues are 
genetically (gene expression) and functionally different from osteoarthritic cells and tissues and 
therefore may respond differently to intervention with exogenous substances. The Panel also notes 
that the evidence provided for the proposed mechanisms which would explain an effect of 
glucosamine on joint cartilage is weak. The Panel considers that results from studies in subjects with 
OA relating to the treatment of symptoms of this disease (e.g. erosion of articular cartilage, and 
reduced function of joints) with glucosamine cannot be extrapolated to the target population. 
Therefore, no scientific conclusions can be drawn from the studies on patients with OA for the 
substantiation of the claimed effect in subjects without OA. 
One publication which reported on two studies (i.e. one observational cross-sectional study and one 
open-label intervention study) in subjects without osteoarthritis was provided. Both studies used 
urinary concentrations of type II collagen fragments as outcome measures. The authors stated that 
fragments of type II collagen were targeted as biomarkers of cartilage synthesis (C-terminal type II 
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procollagen peptide, CPII) and breakdown (C-terminal crosslinking peptide, CTX-II; neoepitope C2C) 
since type II collagen is one of the major constituents of cartilage and represents 90-95 % of the total 
collagen content in cartilage. 
The cross-sectional study was performed to assess the validity of type II collagen fragments in urine 
as outcome measures of joint damage. Urinary concentrations of type II collagen fragments were 
assessed in 21 male soccer players and in 10 male college students who did not participate in any 
college athletics. Urinary concentrations of CTX-II, but not of C2C, were reported to be significantly 
higher in soccer players than in the control subjects (p<0.01), whereas urinary concentrations of CPII 
were not significantly different between the groups. The ratio of CTX-II/CPII in soccer players was 
significantly higher than that in controls (p<0.05). The Panel considers that the evidence provided 
does not establish that changes in urinary concentrations of type II collagen fragments can be used to 
predict joint cartilage degradation. 
The open label intervention was conducted in the sample of soccer players, who received either 1.5 g 
(n=9) or 3 g (n=10) of glucosamine hydrochloride per day for three months. The Panel notes that no 
information was provided on the method used for allocating the subjects to either group, and also 
notes the absence of a placebo control group. Urine samples were collected at baseline, at the end of 
the 3-month intervention with glucosamine, and three months after glucosamine withdrawal. The 
endpoints of the study were urinary concentrations of CTX-II, C2C and CPII, and the CTX-II/CPII 
ratio. The Panel notes that only within-group comparisons between baseline, end of the intervention 
and follow up were reported, and that no statistical comparisons were made for baseline-adjusted 
changes in urinary analytes between the two glucosamine-treated groups. The Panel notes the 
methodological limitations of the study and considers that no conclusions can be drawn from this 
study with respect to the effects of glucosamine hydrochloride on urinary concentrations of type II 
collagen fragments. The Panel also notes that the evidence provided does not establish that changes in 
urinary CTX-II, C2C, CPII or the ratio of CTX-II/CPII over periods of three months can predict net 
changes in joint cartilage in the proposed target population. The Panel considers that no conclusions 
can be drawn from this study for the scientific substantiation of an effect of glucosamine on 
maintenance of joint cartilage. 
The applicant also provided studies on the bioavailability of glucosamine in humans and animals. 
While these studies show that some dietary glucosamine is taken up into blood and synovial fluid, the 
Panel considers that uptake of glucosamine into cartilage cells would be very limited under in vivo 
conditions. 
A number of references were provided on studies performed in animals and in vitro. The Panel 
considers that the evidence provided in the in vitro studies in support of the proposed mechanisms by 
which dietary glucosamine could contribute to the maintenance of joint cartilage in humans is weak, 
and that it was not established that results from animal studies could predict an effect of glucosamine 
on joint cartilage in humans. 
In weighing the evidence, the Panel took into account that no human studies were provided from 
which conclusions could be drawn on the effect of dietary glucosamine on the maintenance of 
cartilage in individuals without osteoarthritis, and that the evidence provided in the in vitro and 
animal studies in support of the biological plausibility for a possible contribution of dietary 
glucosamine to the maintenance of joint cartilage in humans is weak. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of glucosamine and maintenance of normal joint cartilage in individuals without 
osteoarthritis. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 11/10/2011. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 27/10/2011, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 10/11/2011. 
 The scientific evaluation procedure started on 20/11/2011. 
 On 15/12/2011, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 21/12/2011 and restarted on 05/01/2012, in compliance with Art. 18(3) of 
Regulation (EC) No 1924/2006. 
 On 10/01/2012, EFSA received the requested information as submitted by the applicant. 
 During its meeting on 25/04/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to glucosamine 
and maintenance of normal joint cartilage. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: glucosamine and maintenance of 
normal joint cartilage. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of glucosamine, a positive assessment of its safety, nor a decision on whether glucosamine is, or is 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Merck Consumer HealthCare n.v./s.a., Brusselsesteenweg 288, 
BE-3090 Overijse. 
Food/constituent as stated by the applicant 
According to the applicant, glucosamine, formulated as glucosamine sulphate or hydrochloride. 
Health relationship as claimed by the applicant 
According to the applicant, disturbance of tissue homeostasis due to overweight, high mechanical 
load, bad posture or previous injuries and normal aging can lead to cartilage deterioration, which is 
reflected by joint space narrowing and reduced joint functionality. Glucosamine is a major building 
block of joint cartilage tissue, and a physiological inducer of cartilage formation. Glucosamine helps 
to maintain the normal joint cartilage metabolism, which is required for the maintenance of normal 
joints and their appropriate structure and function. 
Wording of the health claim as proposed by the applicant 
The applicant proposed the following wording for the health claim: “Glucosamine contributes to the 
maintenance of normal joint cartilage”. Alternatively: “Glucosamine contributes to the maintenance 
of normal joints”. 
Specific conditions of use as proposed by the applicant 
The applicant proposed an intake of 500-1500 mg of glucosamine per day in usual dosage forms of 
food supplements, i.e. as capsules, tablets, powder or liquids. The indicated amount can be easily 
consumed in the form of food supplements as part of a balanced diet. The target population for this 
health claim is the general population, in particular people exposing their joints to high mechanical 
load, for example through extensive sports activities or obesity, and people with joint cartilage 
deterioration due to normal ageing. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is glucosamine, formulated as glucosamine 
sulphate or hydrochloride. 
Glucosamine is a well characterised amino monosaccharide where a hydroxyl group (-OH) is replaced 
with an amino group (-NH2) (2-amino-2-deoxy-D-glucose). Glucosamine is usually formulated as the 
hydrochloride or as glucosamine sulphate and can be quantified in foods by established methods. 
The Panel considers that the food constituent, glucosamine, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “contributes to the maintenance of normal joint cartilage”. The target population 
as proposed by the applicant is the general population, and in particular people exposing their joints to 
Glucosamine and maintenance of normal joint cartilage 
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high mechanical load, for example through extensive sports activities or obesity, and people with joint 
cartilage deterioration due to normal ageing. 
From the information provided, the Panel notes that the claimed effect relates to the maintenance of 
joint cartilage. For claims on the maintenance of joint cartilage, it is recognised that net loss of 
cartilage may lead to a general loss in joint function. Changes in joint cartilage structure leading to an 
improvement (or reduced loss) in joint function(s) can be considered beneficial physiological effects. 
The Panel considers that the maintenance of normal joint cartilage is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The Panel has already issued an opinion on glucosamine hydrochloride and reduced rate of cartilage 
degeneration and reduced risk of development of osteoarthritis pursuant to Article 14 of Regulation 
(EC) No 1924/2006 with an unfavourable outcome (EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA), 2009a). The Panel has also issued two opinions on glucosamine alone or in 
combination with chondroitin sulphate and maintenance of joints pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006 (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 
2009b) and pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (EFSA Panel on Dietetic 
Products, Nutrition and Allergies (NDA), 2011) with unfavourable outcomes. 
The applicant performed a literature search (databases and search terms not specified) to identify 
human intervention studies (published in English or German) which investigated the effects of 
glucosamine at doses up to 1500 mg daily in healthy subjects or in patients with osteoarthritis (OA) 
on the following primary endpoints: joint space width, Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC), Lequesne, cartilage degradation marker C-terminal crosslinking 
peptide-II (CTX-II), functional marker (e.g. walking test), percentage of joint replacement, and 
magnetic resonance imaging (MRI). Human intervention studies without a control group, without a 
detailed description of the methodology, using “non-validated” biomarkers, on patients with 
rheumatoid arthritis or other joint diseases, using supplementation of glucosamine in combination 
with other substances, assessing only joint pain by visual analogue scales (VAS), or with results 
obtained by post-hoc analysis were excluded. 
Non-human studies were identified by hand search in PubMed using different combinations of the key 
words glucosamine, animal, study, cell-culture, in vitro, and chondrocyte. 
In the original application, the applicant identified a total of 61 references as being pertinent to the 
health claim. These comprised 20 references describing 12 human intervention studies 
(11 randomised controlled trials (RCT), one open label intervention study), 13 reviews on the effects 
of glucosamine supplementation on maintenance of joints, four animal studies on the effects of 
glucosamine on joints, 14 in vitro studies on the effects of glucosamine on cartilage cells/tissues, nine 
studies in humans and/or animals on the bioavailability of glucosamine, and one unpublished 
narrative review on putative mechanisms for cartilage degradation and development/progression of 
OA. 
Human studies in patients with osteoarthritis 
The applicant provided 19 references which reported on 11 human intervention studies. These studies 
addressed the effects of glucosamine sulphate (10 studies) or glucosamine hydrochloride (one study) 
on joint-related outcomes (e.g. joint space width in three studies, and joint function in eight studies) in 
patients with clinical diagnosis of degenerative OA, mainly of the knee (Bruyere et al., 2003, 2004, 
2008; Christgau et al., 2004; Cibere et al., 2004; Clegg et al., 2006; Drovanti et al., 1980; Frestedt et 
al., 2008; Herrero-Beaumont et al., 2007; Houpt et al., 1999; Hughes and Carr, 2002; Kawasaki et al., 
2008; McAlindon et al., 2004; Noack et al., 1994; Pavelka et al., 2002; Reginster et al., 2001; 
Glucosamine and maintenance of normal joint cartilage 
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Rozendaal et al., 2008; Usha and Naidu, 2004; Zenk et al., 2002). The applicant proposed that results 
from these studies in patients with OA could be extrapolated to subjects without OA on the 
assumption that cartilage degeneration occurs by the same metabolic pathways and mechanisms 
during progression of OA as in pre-arthritic conditions, and that glucosamine may be expected to have 
similar effects on joint tissues with and without OA (Alexander et al., 2010, unpublished). 
The applicant was invited to comment on recent expert reviews which indicate that there is lack of 
agreement on the specific cellular and molecular mechanisms by which cartilage degeneration occurs 
in the development (onset) and progression of osteoarthritis. In reply, the applicant indicated that a 
very good consensus has been established concerning the various mechanisms and pathways 
contributing to cartilage deterioration and osteoarthritis development. The applicant provided several 
references to factors that are considered to contribute to cartilage metabolism as well as putative 
mechanisms for cartilage degradation associated with the onset of OA as a result of joint overloading, 
ageing and obesity, as well as for cartilage degradation associated with progression of OA (e.g. 
Bronner and Farach-Carson, 2007; Hunter, 2008, 2011; Lane et al., 2011; Malemud, 2010). The Panel 
notes that while a number of factors which may contribute to cartilage degeneration in the 
development (onset) and progression of OA have been identified, the term OA denotes a number of 
pathological degenerative processes of one or more joints of complex and variable aetiology for 
which no common pathological pathway has been described. The Panel also notes, in particular, that 
the pathobiology of the onset and early progression of OA is poorly defined. The evidence provided 
by consensus opinions/reports from authoritative bodies indicates that normal cells and tissues are 
genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and 
therefore may respond differently to intervention with exogenous substances (FDA, 2004a,b; Jordan 
et al., 2011). The Panel also notes that the evidence provided for the proposed mechanisms which 
would explain an effect of glucosamine on joint cartilage is weak (see below). The Panel considers 
that results from studies in subjects with OA relating to the treatment of symptoms of this disease 
(e.g. erosion of articular cartilage, and reduced function of joints) with glucosamine cannot be 
extrapolated to the target population. Therefore, no scientific conclusions can be drawn from the 
studies on patients with OA for the substantiation of the claimed effect in subjects without OA. 
Human studies in subjects without osteoarthritis 
One publication (Yoshimura et al., 2009) reported on one observational cross-sectional study and one 
open-label intervention study which used urinary concentrations of type II collagen fragments as 
outcome measures. The authors stated that fragments of type II collagen were targeted as biomarkers 
of cartilage synthesis (C-terminal type II procollagen peptide, CPII) and breakdown (C-terminal 
crosslinking peptide, CTX-II; neoepitope C2C) since type II collagen is one of the major constituents 
of cartilage and represents 90-95 % of the total collagen content in cartilage. 
The cross-sectional study was performed to assess the validity of type II collagen fragments in urine 
as outcome measures of joint damage (Yoshimura et al., 2009). Urinary concentrations of type II 
collagen fragments were assessed in 21 male soccer players (19-22 years of age) and in 10 male 
college students (controls, 20-27 years of age). Soccer players were training five times a week for 
about 2 h/day, whereas the control subjects did not participate in any college athletics, nor had 
experienced moderate or hard exercise for over one year. Urinary concentrations of CTX-II, 
neoepitope C2C and CPII were measured in second void morning urine samples and were 
standardised for creatinine. Urinary concentrations of CTX-II, but not of C2C, were reported to be 
significantly higher in soccer players than in the control subjects (p<0.01), whereas urinary 
concentrations of CPII were not significantly different between the groups. The ratio of CTX-II/CPII 
in soccer players was significantly higher than that in controls (p<0.05). 
The applicant was invited to provide justification for the validity of the biomarkers used in the study 
to assess the claimed effect, i.e. evidence that changes in the biomarkers used over periods of, for 
example, three months can predict net changes in joint cartilage in the proposed target population. In 
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reply, the applicant claimed that while it is not possible to establish a correlation between such 
biomarkers and net changes in joint cartilage, CTX‐II is a well-established prognostic biomarker and 
independent risk factor of joint cartilage breakdown in the progression of osteoarthritis, and is a 
suitable surrogate indicator for chondroprotective effects of supplements and medicinal products, 
including glucosamine. A number of studies were provided by the applicant on the use of urinary 
concentrations of type II collagen fragments (mainly on urinary CTX‐II) as markers for diagnosis of 
OA and for the progression of joint damage during development, progression and treatment of OA 
(Bay‐Jensen et al., 2009; Cahue et al., 2007; Cheras et al., 2010; Christgau et al., 2001; Christgau et 
al., 2004; Cibere et al., 2009; Dam et al., 2009; Garnero et al., 2001, 2002a, 2003; Iwamoto et al., 
2010; Karsdal et al., 2010; Kumm et al., 2009; Mazieres et al., 2006; Reijman et al., 2004; Scarpellini 
et al., 2008; Sharif et al., 2007; Sowers et al., 2009; Syversen et al., 2009; Tanishi et al., 2009; Watari 
et al., 2008), rheumatoid arthritis (Christensen et al., 2009; Garnero et al., 2002b; Hashimoto et al., 
2009; van Tuyl et al., 2010) and other joint disorders (Jansen et al., 2009; Rousseau et al., 2010). The 
applicant also claimed that urinary CTX‐II is a suitable early indicator of joint cartilage damage in 
healthy subjects, e.g. upon repetitive physical joint loading, as in sports (Yoshimura et al., 2009-cross-
sectional study), and that increased urinary concentrations of CTX-II in menopausal women correlate 
with a higher prevalence of OA (Mouritzen et al., 2003). The Panel considers that while the studies 
provided by the applicant may indicate an association between urinary concentrations of type II 
collagen fragments and joint cartilage damage in certain population subgroups, the evidence provided 
does not establish that changes in urinary concentrations of type II collagen fragments can be used to 
predict joint cartilage degradation. This conclusion is in agreement with what is generally accepted by 
experts in the field, as indicated in a recent consensus report (Kraus et al., 2011). 
The open label intervention (Yoshimura et al., 2009) was conducted in the sample of soccer players, 
who received either 1.5 g (n=9) or 3 g (n=10) of glucosamine hydrochloride per day for three months. 
The Panel notes that no information was provided on the method used for allocating the subjects to 
either group, and also notes the absence of a placebo control group. Second void morning urine 
samples were collected at baseline, at the end of the 3-month intervention with glucosamine, and three 
months after glucosamine withdrawal (follow-up). The endpoints of the study were urinary 
concentrations of CTX-II, C2C and CPII, all standardised for creatinine, and the CTX-II/CPII ratio. 
The Panel notes that only within-group comparisons between baseline, end of the intervention and 
follow up were reported, and that no statistical comparisons were made for baseline-adjusted changes 
in urinary analytes between the two glucosamine-treated groups. The Panel notes the methodological 
limitations of the study and considers that no conclusions can be drawn from this study with respect to 
the effects of glucosamine hydrochloride on urinary concentrations of type II collagen fragments. The 
Panel also notes that the evidence provided does not establish that changes in urinary CTX-II, C2C, 
CPII or the ratio of CTX-II/CPII over periods of three months can predict net changes in joint 
cartilage in the proposed target population. The Panel considers that no conclusions can be drawn 
from this study for the scientific substantiation of an effect of glucosamine on maintenance of joint 
cartilage. 
Mechanistic studies 
The applicant provided data on the bioavailability of glucosamine in support of the biological 
plausibility of the claim (Akarasereenont et al., 2009; Block et al., 2010; Meulyzer et al., 2009; 
Oegema et al., 2002; Persiani et al., 2005, 2007; Setnikar et al., 1986, 1993; Setnikar and Rovati, 
2001; Zhang et al., 2006; Zhu et al., 2009). A review by Block et al. (2010) concluded that the 
concentrations of glucosamine in the blood of subjects receiving 1500 mg of glucosamine per day 
reaches a maximum of about 10 µM between 1 and 4 h after ingestion, followed by a significant 
decline by about 6-8 h. Results were similar for glucosamine hydrochloride and sulphate. The mean 
concentration of glucosamine achieved in the synovial fluid 3 h after administration is around 80 % of 
the mean blood concentration (Persiani et al., 2007). No information was provided on the uptake of 
exogenous glucosamine into joint cartilage cells (e.g. chondrocytes). However, the Panel notes that 
cellular uptake of exogenous glucosamine at extracellular concentrations of 10 µM would be very 
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limited in vivo owing to competition with much higher concentrations (about 5 mM) of glucose 
(Block et al., 2010). 
The applicant proposed a number of mechanisms by which dietary glucosamine could contribute to 
the maintenance of joint cartilage. These include: (1) oral glucosamine is an exogenous source of 
glucosamine for glycosaminoglycan (GAG) synthesis, (2) oral glucosamine supports cartilage 
homeostasis, e.g. by inhibiting the gene expression of matrix metalloproteases in chondrocytes and 
synovial fibroblasts, or up-regulating the expression of TGF-β1 in chondrocytes, (3) glucosamine 
prevents joint degeneration owing to its anti-inflammatory properties. 
A number of in vitro studies on the effect of glucosamine on cartilage formation/degradation were 
provided (Byron et al., 2008; Chan et al., 2005; Derfoul et al., 2007; Dodge and Jimenez, 2003; Largo 
et al., 2003; Lin et al., 2008; Lippiello, 2007; Lu et al., 2008; Sandy et al., 1999; Shikhman et al., 
2001; Toegel et al., 2008; Uitterlinden et al., 2008; Varghese et al., 2007; Wei and Haut, 2009). The 
applicant was invited to provide a rationale on why any effects of glucosamine in vitro could predict 
effects in vivo in humans, taking into consideration the experimental conditions for these studies, e.g. 
concentrations of glucosamine used compared to concentrations of glucosamine achievable in vivo 
with a dietary intake of 1.5 g/d. The applicant did not address the question regarding the experimental 
conditions of these studies directly. Regarding a possible contribution of dietary glucosamine to GAG 
synthesis, the evidence provided included references on in vitro effects of glucosamine on cartilage 
tissue explants and chondrocytes in culture, including effects of glucosamine on the synthesis of 
cartilage components such as glycosaminoglycans (Bassleer et al., 1998; Byron et al., 2008; Derfoul 
et al., 2007; Toegel et al., 2008; Uitterlinden et al., 2008; Varghese et al., 2007). In almost all of these 
studies the concentrations of glucosamine at which effects were observed considerably exceeded 
those that are achieved in blood and synovial fluid in humans with a daily intake of 1500 mg of 
glucosamine. The Panel notes that no evidence was provided that endogenous synthesis of 
glucosamine from glucose and glutamine is insufficient for the maintenance of normal cartilage in 
subjects without OA. A contribution of dietary glucosamine to the synthesis of cartilage components 
(GAG) requires exogenous glucosamine to be taken up by chondrocytes in sufficient quantities. At 
achievable concentrations (~10 µM) in synovial fluid with a daily intake of 1500 mg glucosamine, 
two reviews concluded that the contribution of dietary glucosamine to the synthesis of GAG would be 
negligible (Silbert, 2009; Block et al., 2010). This conclusion takes into account the competition of 
glucosamine with much higher concentrations of glucose for uptake into cartilage cells, and the large 
excess of endogenously produced glucosamine for incorporation into GAG. 
Regarding other proposed mechanisms, the evidence provided included references on in vitro effects 
of glucosamine on cartilage tissue explants and chondrocytes in culture, including effects of 
glucosamine on pro-inflammatory cytokines (Chan et al., 2005; Derfoul et al., 2007; Largo et al., 
2003; Lin et al., 2008; Lu et al., 2008; Sandy et al., 1999; Shikhman et al., 2001; Toegel et al., 2008), 
and degradative enzymes (Derfoul et al., 2007; Dodge and Jimenez, 2003; Lin et al., 2008; Lu et al., 
2008; Varghese et al., 2007). The Panel notes that the concentrations of glucosamine used in almost 
all of these studies considerably exceeded those that are achieved in blood and synovial fluid in 
humans with a daily intake of 1500 mg glucosamine. 
The Panel considers that the evidence provided in the in vitro studies in support of the proposed 
mechanisms by which dietary glucosamine could contribute to the maintenance of joint cartilage in 
humans is weak. 
The applicant also provided studies in animals on the effect of glucosamine on cartilage 
formation/degradation (Chen et al., 2010; Meulyzer et al., 2009; Naito et al., 2010; Oegema et al., 
2002; Taniguchi et al., 2012). Four studies were provided in animal models of OA, i.e. in rats and 
rabbits with OA induced surgically or enzymatically (Chen et al., 2010; Naito et al., 2010; Oegema et 
al., 2002) and in Hartley guinea pigs susceptible to spontaneous OA (Taniguchi et al., 2012). One 
study was provided on the effect of glucosamine on induced (by injection of lipopolysaccharides from 
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E. coli) inflammation of joints in horses (Meulyzer et al., 2009). The applicant was invited to justify 
the validity of the animal models in the context of the claimed effect, i.e. reasons why any effect of 
glucosamine in those animal studies could predict an effect on joint cartilage in the target population. 
The applicant did not address the question regarding the validity of these animal models directly. The 
Panel notes the lack of justification for the validity of these models. The Panel considers that the 
evidence provided does not establish that results from animal studies could predict an effect of 
glucosamine on joint cartilage in humans. 
The Panel considers that the evidence provided in the in vitro and animal studies in support of the 
biological plausibility for a possible contribution of dietary glucosamine to the maintenance of joint 
cartilage in humans is weak. 
In weighing the evidence, the Panel took into account that no human studies were provided from 
which conclusions could be drawn on the effect of dietary glucosamine on the maintenance of 
cartilage in individuals without osteoarthritis, and that the evidence provided in the in vitro and 
animal studies in support of the biological plausibility for a possible contribution of dietary 
glucosamine to the maintenance of joint cartilage in humans is weak. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of glucosamine and maintenance of normal joint cartilage in individuals without 
osteoarthritis. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, glucosamine, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect is “contributes to the maintenance of normal joint cartilage”. The target 
population as proposed by the applicant is the general population, and in particular people 
exposing their joints to high mechanical load, for example through extensive sports activities 
or obesity, and people with joint cartilage deterioration due to normal ageing. Maintenance of 
normal joint cartilage is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
glucosamine and maintenance of normal joint cartilage in individuals without osteoarthritis. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on glucosamine and “contributes to the maintenance of normal joint 
cartilage” pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0313_BE). 
November 2011. Submitted by Merck Consumer HealthCare. 
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GLOSSARY / ABBREVIATIONS 
CPII  C-terminal type II procollagen peptide 
CTX-II  C-terminal crosslinking peptide 
GAG  glycosaminoglycan 
MRI  magnetic resonance imaging 
OA  osteoarthritis 
RCT  randomised controlled trial 
TGF-β1 transforming growth factor beta 1 
VAS  visual analogue scales 
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index 
